Search results for " diabetes"

showing 10 items of 2906 documents

Hemostatic function in young subjects with central obesity: relationship with left ventricular function.

1995

This study was designed to evaluate coagulation and fibrinolysis activity and their relationship with left ventricular function in young obese subjects with central fat distribution. We assessed coagulation and fibrinolysis activity by evaluation of factor VII activity, fibrinogen and plasminogen, plasminogen activator inhibitor (PAI), and tissue plasminogen activator antigen basally (tPA1) and after venous occlusion (tPA2). These measures were evaluated in young (< 40 years) obese subjects with central fat distribution (n = 19) and in comparable lean subjects (n = 20). Blood glucose, triglycerides, total and high-density lipoprotein (HDL) cholesterol, apolipoprotein (apo) A1 and apo B, fas…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaApolipoprotein BEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenVentricular Function LeftSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundEndocrinologyWaist–hip ratioInternal medicineFibrinolysismedicineHumansInsulinObesityHemostatic functionBlood CoagulationApolipoproteins ATriglyceridesApolipoproteins BHemostasisbiologybusiness.industryCholesterolCholesterol HDLFibrinogenCentral obesity Hemostatic function left ventricular functionPlasminogenFactor VIISettore MED/11 - Malattie Dell'Apparato CardiovascolarePlasminogen InactivatorsEndocrinologychemistrybiology.proteinBody ConstitutionRegression AnalysisFemalebusinessPlasminogen activatormedicine.drugLipoproteinMetabolism: clinical and experimental
researchProduct

Prediction of incident type 2 diabetes mellitus based on a twenty-year follow-up of the Ventimiglia heart study.

2011

A novel algorithm to predict incident type 2 diabetes mellitus (iT2DM) is presented considering data from a 20-year prospective study in a Southern Italy population. Eight hundred and fifty-eight out of 1,351 subjects (24-85 years range of age) were selected. Incident type 2 diabetes was diagnosed in 103 patients in a 20-year follow-up. The Finnish Diabetes Risk Score (FINDRISC) and the Framingham Offspring Study simple clinical model (FOS) have been used as reference algorithms. Two custom algorithms have been created using Cox parametric hazard models followed by PROBIT analyses: the first one (VHSRISK) includes all the study subjects and the second one (VHS95RISK) evaluates separately su…

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismPopulationType 2 diabetesLower riskBody Mass IndexYoung AdultEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineHumansProspective StudieseducationPopulation study Epidemiology Predictive models Incident diabetes mellitusAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyFramingham Risk Scorebusiness.industryType 2 Diabetes MellitusGeneral MedicineCholesterol LDLFastingMiddle Agedmedicine.diseaseSurgeryDiabetes Mellitus Type 2ItalyPopulation studyFemaleMetabolic syndromebusinessFollow-Up StudiesActa diabetologica
researchProduct

Sympathovagal balance and 1-h postload plasma glucose in normoglucose tolerant hypertensive patients.

2015

AIMS: Normoglucose tolerant (NGT) subjects with a 1-h postload plasma glucose (PLPG) value ≥155 mg/dL have an increased risk of type-2 diabetes and subclinical organ damage. Heart rate variability (HRV) reflects cardiac autonomic balance, frequently impaired in course of diabetes. At this time, no data support the association between 1-h PLPG and HRV; thus, we investigated the possible association between 1-h PLPG and HRV. METHODS: We enrolled 92 never-treated hypertensive subjects (56 women, 36 men), aged 55 ± 9.8 years. During OGTT, the patients underwent electrocardiographic recordings to evaluate HRV in the time domain (SDNN). Insulin sensitivity was assessed by Matsuda index. RESULTS: …

AdultBlood GlucoseMalemedicine.medical_specialtySettore MED/09 - Medicina Internaendocrine system diseasesglucose toleranceInsulin resistance Heart rate variability Glucose tolerance Essential hypertensionEndocrinology Diabetes and Metabolismmedicine.medical_treatment030209 endocrinology & metabolism030204 cardiovascular system & hematologyEssential hypertensionAutonomic Nervous Systeminsulin resistance heart rate variability glucose tolerance essential hypertensionImpaired glucose tolerance03 medical and health sciences0302 clinical medicineEndocrinologyInsulin resistanceHeart RateInternal medicineDiabetes mellitusinsulin resistanceGlucose IntoleranceInternal MedicineMedicineHeart rate variabilityHomeostasisHumansSubclinical infectionBalance (ability)Agedbusiness.industryInsulinheart rate variabilityessential hypertensionnutritional and metabolic diseasesGeneral MedicineGlucose Tolerance TestMiddle Agedmedicine.diseaseEndocrinologyDiabetes Mellitus Type 2HypertensionCardiologyFemalebusinesshormones hormone substitutes and hormone antagonists
researchProduct

The Metabolic Profile in Active Acromegaly is Gender-Specific.

2012

CONTEXT: The sexual dimorphism of the somatotroph axis has been documented, but whether the acromegaly-related metabolic alterations are gender-dependent has never been investigated. OBJECTIVE: The aim of the study was to evaluate the impact of gender on the metabolic parameters in acromegaly. DESIGN: We conducted a retrospective, comparative, multicenter study. PATIENTS: The 307 newly diagnosed acromegalic patients included in the study were grouped by gender: 157 men (aged 48.01 ± 14.28 yr), and 150 women (aged 48.67 ± 14.95 yr; of which 77 were premenopausal and 73 postmenopausal). OUTCOME MEASUREMENTS: We measured each component of the metabolic syndrome (MS), hemoglobin A1c, the areas …

AdultBlood GlucoseMalemedicine.medical_specialtySomatotropic cellEndocrinology Diabetes and Metabolismmedicine.medical_treatmentClinical BiochemistryContext (language use)Intra-Abdominal FatBiochemistrySettore MED/13 - EndocrinologiaCohort StudiesEndocrinologyInsulin resistanceInternal medicineAcromegalygendermedicineHumansInsulinAgedRetrospective StudiesSex Characteristicsbusiness.industryInsulinBiochemistry (medical)FastingMiddle Agedmedicine.diseasemetabolic profileObesitySexual dimorphismEndocrinologyAcromegalyMetabolomeFemaleMetabolic syndromeInsulin Resistancebusiness
researchProduct

Glycaemic variability and inflammation in subjects with metabolic syndrome.

2008

Subjects who develop diabetes have an increased cardiovascular risk even before the appearance of diabetes. The aim of this study was to investigate the glycaemic variability measured by continuous glucose monitoring (CGM CV%) in nondiabetic subjects with metabolic syndrome (MS) and to explore if glycaemic variability was associated with circulating levels of interleukin-6 (IL-6), a proinflammatory cytokine, or with an anti-inflammatory factor like adiponectin. Three groups of obese subjects with (MS+: 6m, 8f; BMI 33.1 ± 1.4 mean ± SEM) or without metabolic syndrome (MS−: 2m, 4f; BMI 29.2 ± 2.2) and with MS associated with type 2 diabetes (MS/T2D: 3m, 5f; BMI 32.9 ± 1.4) were investigated. …

AdultBlood GlucoseMalemedicine.medical_specialtyWaistendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentMonitoring AmbulatoryBlood sugarType 2 diabetesBody Mass IndexEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineHumansObesityMetabolic SyndromeAdiponectinbusiness.industryInsulinReproducibility of Resultsnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseObesityEndocrinologyFemaleWaist CircumferenceMetabolic syndromeVariabilità glicemica flogosi sindrome metabolicabusiness
researchProduct

The effect of growth hormone ( GH ) replacement on blood glucose homeostasis in adult nondiabetic patients with GH deficiency: real‐life data from th…

2015

SummaryObjective To assess the effect of 4 years’ growth hormone (GH) replacement on glucose homeostasis and evaluate factors affecting glycosylated haemoglobin (HbA1c) in adults with growth hormone deficiency (GHD). Design NordiNet® International Outcome Study, a noninterventional study, monitors long-term effectiveness and safety of GH replacement [Norditropin® (somatropin), Novo Nordisk A/S] in real-life clinical practice. Patients Nondiabetic patients (n = 245) with adult-onset GHD (age ≥20 years at GH start), ≥4 years’ GH replacement and HbA1c values at baseline and 4 years were included in the analysis. Measurements Changes from baseline (∆) to 4 years in HbA1c, fasting plasma glucose…

AdultBlood GlucoseMalemedicine.medical_specialtyWaistendocrine system diseasesHormone Replacement TherapyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolism030204 cardiovascular system & hematologyGrowth hormone deficiencyImpaired glucose toleranceYoung Adult03 medical and health sciences0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusDiabetes MellitusmedicineHomeostasisHumansGlucose homeostasisYoung adultAgedAged 80 and overGlycated Hemoglobinbusiness.industrynutritional and metabolic diseasesMiddle Agedmedicine.diseaseSomatropinTreatment OutcomeEndocrinologyGrowth HormoneFemalebusinessBody mass indexClinical Endocrinology
researchProduct

Behavior of the total antioxidant status in a group of subjects with metabolic syndrome.

2014

AIM: Our purpose was to examine the total antioxidant status (TAS) in subjects with metabolic syndrome (MS) subdivided according to the presence or not of diabetes mellitus. METHODS: We enrolled 106 subjects (45 women, 61 men) with MS subsequently subdivided in diabetics (14 women, 29 men) and nondiabetics (31 women, 29 men). TAS was obtained using an Assay kit which relies on the ability of plasma antioxidant substances to inhibit the oxidation of 2,2'-azino-bis(3-ethylbenzthiazoline sulfonic acid) to the radical ABTS+. RESULTS: In the group of MS subjects a significant decrease in TAS (p<0.05) in comparison with normal controls was evident. This difference was present between normal subje…

AdultBlood GlucoseMalemedicine.medical_specialtyanimal structuresAntioxidantSettore MED/09 - Medicina InternaBilirubinEndocrinology Diabetes and Metabolismmedicine.medical_treatmentBlood PressureAntioxidantschemistry.chemical_compoundInternal medicineDiabetes mellitusInternal MedicinemedicineHumansAgedMetabolic SyndromeABTSbusiness.industryBilirubinGeneral MedicineMiddle Agedmedicine.diseasePathophysiologyTOTAL ANTIOXIDANT STATUS METABOLIC SYNDROMEUric AcidAntioxidant capacityOxidative StressEndocrinologychemistryDiabetes Mellitus Type 2ItalyLinear ModelsUric acidFemaleMetabolic syndromebusiness
researchProduct

Prevalence of diabetes mellitus and impaired glucose tolerance in cystic fibrosis.

1990

The aim of this study was to evaluate the prevalence of impaired glucose tolerance or diabetes mellitus in 99 patients (53 M, 46 F; mean age 10.5 +/- 6.9 years), with cystic fibrosis. Glucose tolerance was evaluated in all patients without overt diabetes using the oral glucose tolerance test (OGTT). Six patients showed a pathological OGTT and 2 patients had insulin-requiring diabetes mellitus. The mean age of the patients with impaired glucose tolerance was significantly higher than that of the subjects with normal glucose metabolism (p less than 0.0001). Patients with overt diabetes mellitus were the oldest subjects in the study group.

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesAdolescentCystic FibrosisEndocrinology Diabetes and MetabolismStatistics as TopicCarbohydrate metabolismGastroenterologyCystic fibrosisImpaired glucose toleranceEndocrinologyInternal medicineDiabetes mellitusEpidemiologyInternal MedicinemedicineDiabetes MellitusPrevalenceHumansChildPathologicalGlucose tolerance testmedicine.diagnostic_testbusiness.industrynutritional and metabolic diseasesInfantGeneral MedicineGlucose Tolerance Testmedicine.diseaseEndocrinologyChild PreschoolFemalebusinessComplicationActa diabetologica latina
researchProduct

Professional continuous glucose monitoring in subjects with type 1 diabetes: retrospective hypoglycemia detection.

2013

Background: An important task in diabetes management is detection of hypoglycemia. Professional continuous glucose monitoring (CGM), which produces a glucose reading every 5 min, is a powerful tool for retrospective identification of unrecognized hypoglycemia. Unfortunately, CGM devices tend to be inaccurate, especially in the hypoglycemic range, which limits their applicability for hypoglycemia detection. The objective of this study was to develop an automated pattern recognition algorithm to detect hypoglycemic events in retrospective, professional CGM. Method: Continuous glucose monitoring and plasma glucose (PG) readings were obtained from 17 data sets of 10 type 1 diabetes patients und…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismBiomedical EngineeringBioengineeringHypoglycemiaSensitivity and SpecificityAutomationDiabetes managementBlood Glucose Self-MonitoringDiabetes mellitusInternal MedicineMedicineHumansIntensive care medicineGlycemicMonitoring PhysiologicRetrospective StudiesType 1 diabetesbusiness.industryContinuous glucose monitoringBlood Glucose Self-Monitoringnutritional and metabolic diseasesRetrospective cohort studyMiddle Agedmedicine.diseaseHypoglycemiaDiabetes Mellitus Type 1Original ArticlebusinessAlgorithmsJournal of diabetes science and technology
researchProduct

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

2003

Pharmacokinetic and pharmacodynamic profiles of the rapid-acting insulin analogues lispro and aspart were compared in a randomized, double-blind crossover study of 20 fasting healthy men following a single subcutaneous injection. Either insulin lispro or aspart, 0.05 U/kg-body-weight, was injected subcutaneously and followed by determination of 5-h profiles of plasma glucose, serum C-peptide and insulin concentrations. Lowest glucose concentrations were observed after 50 min in the aspart group (3.2 +/- 0.1 mmol/l versus lispro 3.5 +/- 0.1 mmol/l; p = 0.026) and after 60 min in the lispro group (3.4 +/- 0.1 mmol/l). For blood glucose t min was 59.3 +/- 3.4 min in the aspart and 63.5 +/- 5.3…

AdultBlood GlucoseMalemedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRadioimmunoassayInsulin aspartSubcutaneous injectionEndocrinologyPharmacokineticsDouble-Blind MethodDiabetes mellitusInternal medicineInternal MedicinemedicineInsulin lisproHumansHypoglycemic AgentsInsulinInsulin AspartCross-Over StudiesInsulin LisproC-Peptidebusiness.industryInsulindigestive oral and skin physiologynutritional and metabolic diseasesGeneral Medicinemedicine.diseaseCrossover studyEndocrinologyPharmacodynamicsbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental and clinical endocrinologydiabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
researchProduct